MIT/Harvard mRNA Adjuvant Strategy Eradicates Most Tumors in Mice, Amplifies T-Cell Response 10–15×

On May 13, 2026, MIT News reported a major preclinical advance in mRNA cancer vaccine technology developed by researchers from MIT, Harvard, and the University of Houston. Published in Nature Biotechnology, the study describes encoding two immune-signaling genes — IRF8 and NIK — into mRNA molecules to create a supercharged dendritic cell and T-cell response. In mouse models of melanoma and lymphoma, the mRNA-encoded adjuvant strategy eradicated most tumors when used alone or combined with tumor antigen mRNA vaccines. When paired with COVID-19 and influenza mRNA vaccines, it produced 10–15× stronger T-cell responses. The approach also enhanced responses to checkpoint inhibitor (anti-PD-1) therapies. IRF8 is a transcription factor critical for dendritic cell maturation; NIK activates the non-canonical NF-κB pathway. Unlike chemical adjuvants, this strategy allows the immune-boosting signals to be encoded alongside vaccine antigens in a single LNP formulation, enabling precise co-delivery. The University of Houston issued a complementary press release on May 19, 2026, broadening coverage. Researchers cautioned that mouse data are promising but human trials are needed to confirm translation of the effect.